Vergent Bioscience came out of stealth mode today to reveal a nearly $9 million equity offering for the injectable molecular probe it’s developing to visualize tumors during surgery. Minneapolis-based Vergent Bioscience’s technology uses a proprietary injectable, tumor-targeting molecule that binds to tumor cells and fluoresces, president & CEO John Santini told MassDevice.com last week at the DeviceTalks […]